wannabeeriche
3 days ago
Do WE Vote YES, NO, or ABSTAIN
BNGO did a reverse split of 1 for 10 in August 2023. Since then, Erik Holmlin
Increased (diluted) BNGO shares by 89 MILLION, raising money for the Company.
A number of shareholders highlight the fact the Company is in dire straits, however Erik
never took a pay cut to help out.
BNGO will hold a shareholders meeting on January 15,2025. On the agenda are the following:
A reverse split for either 1 for 25 or 1 for 75, and increasing (diluting) overall share by 19 million.
My question is, and I am looking for advice: Do we vote YES, NO, or ABSTAIN?
So, if you how have 25,000 shares of BNGO, and the reverse comes, you will
either have 1,000 shares or 333 shares.
Comments, Please!
wannabeeriche
6 days ago
Investors & Advocates For Approval of OGM
Thereβs a new sheriff is in town: Robert F. Kennedy Jr. Robert F. Kennedy Jr. has been quite vocal about his plans to overhaul the FDA.
When researchers, clinicians, and investors come together to advocate for a promising technology, it can bring attention to its potential benefits and the urgency of its approval.
Public pressure, combined with robust research and evidence (Worldwide acceptance), can expedite the regulatory process. It's important to continue raising awareness and ensuring that the voices of those who support OGM are heard.
Here's a draft of an open letter you can use to advocate for the approval of Bionano Genomics' Optical Genome Mapping (OGM):
[Your Name] [Your Address] [City, State, ZIP Code] [Email Address] [Date]
Dr. Jeffrey Shuren
Director, Center for Devices and Radiological Health Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-000
Dear Dr. Shuren,
I am writing to express my strong support for the approval of Bionano Genomics' Optical Genome Mapping (OGM) technology. As a [researcher/investor/clinician/advocate], I believe that OGM has the potential to revolutionize genomic analysis and diagnostics, providing significant benefits to patients and the healthcare community.
The acceptance of OGM by prestigious institutions such as the Mayo Clinic and Johns Hopkins underscores its credibility and potential. Furthermore, extensive testing and research conducted worldwide have demonstrated the efficacy and safety of this technology. However, despite these promising developments, the approval process for OGM appears to be facing unnecessary delays.
I urge the FDA, specifically the Office of Health Technology 7 (OHT7), to prioritize the evaluation and approval of OGM. The timely approval of this technology is crucial for advancing genomic research and improving patient outcomes.
Thank you for your attention to this matter. I look forward to a positive resolution and the continued advancement of genomic science.
Sincerely, [Your Name]
(lets start a ground swell of getting the FDA to approve OGM)
georgie18
1 month ago
BNGO...29...No Position...🥳...just watching to see where she lands following this offering...SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the βWarrantsβ) at a combined offering price of $0.3039 per share of common stock and accompanying Warrants, in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the βStockholder Approvalβ). The Series C warrants will expire five years following the date of the Stockholder Approval and the short-term Series D warrants will expire eighteen months following the date of Stockholder Approval. The closing of the offering is expected to occur on or about October 31, 2024, subject to the satisfaction of customary closing conditions.